La empresa israelí de inmunoterapia en fase clínica, Enlivex Therapeutics, anunció la compra de Bitcoin como reserva de activos de la empresa

Wu learned that Enlivex Therapeutics, an Israeli clinical-stage immunotherapy company, announced that its board of directors has approved the purchase of up to $1 million worth of BTC as part of its cash management strategy. The company is listed on the Nasdaq in the United States (code: ENLV), and CEO Oren Hershkovitz said that with the increasing demand and acceptance of BTC, as well as the recent approval of BTC ETFs and support from institutional investors, the company believes that BTC can serve as a strong asset reserve, providing value storage and inflation resistance.

Ver originales
  • Recompensa
  • Comentar
  • Compartir
Comentar
0/400
Sin comentarios
Comercie con criptomonedas en cualquier lugar y en cualquier momento
qrCode
Escanee para descargar la aplicación Gate.io
Comunidad
Español
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский
  • Français (Afrique)
  • Português (Portugal)
  • ไทย
  • Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)